The Ramada strain is currently referred to by the World Health Organization as a “virus under observation” (VOI), and the symptoms of infection with the Ramada variant are essentially the same as those commonly seen with the new coronavirus. Early infection may be asymptomatic, with muscle aches and peripheral weakness. As the disease progresses, patients may develop fever, with most having a temperature of 37.3°C or higher. Patients may also develop respiratory symptoms, such as nasal congestion, sore throat, cough, and even discomfort such as diarrhea, chest tightness, and panic. Due to individual differences, some patients will turn into heavy and critical forms, and even involve the central nervous system. The Ramada mutant strain of NIV is highly infectious, and the unique 7 amino acid deletion mutation in the N-terminal structural domain of the protein may lead to the strain’s ability to evade neutralizing antibodies. Therefore, there is a possibility of “breakthrough infection”, i.e., the possibility of infection with neocoronavirus even after vaccination with neocoronavirus. However, there is insufficient evidence that the NCC vaccine is ineffective against the mutated strain, and active vaccination against NCC is still recommended. In particular, people in moderate-to-high risk areas should be tested for neo-coronavirus in a timely manner, and close contacts should be actively screened. It is important to strengthen self-protection and awareness of health and civilization in daily life, enhance personal hygiene protection, actively correspond to national outbreak prevention and control efforts, and maximize recovery from daily life.